MiniMed Q1 Sales Jump 17%, Raises FY27 Growth Outlook on U.S. Acceleration
MMED sits 88% above its 52-week low of $10.65 on elevated volume (2.0× avg).
Summary
MiniMed reported Q1 FY27 net sales of $843M, up 16.6% reported and 15.8% organic, beating expectations. U.S. growth accelerated to 13.1% driven by the MiniMed Flex™ launch and new sensor uptake, while international sales grew 18.1%. The company raised FY27 organic revenue growth guidance to ~10.5% from ~10%, citing strong demand and pipeline momentum. Pipeline milestones include FDA submission for MiniMed Fit™ ahead of schedule, CE Mark for MiniMed Flex™, completion of Vivera™ pivotal trial enrollment, and IDE approval for a next-gen sensor. Q1 EPS was 0 cents. This follows the June 2026 annual report showing widening losses and negative operating cash flow, but today's results signal improving commercial traction.
At the time of this announcement, MMED was trading at $20.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7B. The 52-week trading range was $10.65 to $20.88. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: PR Newswire.